Skip to content
PatientMatchFind trials
Study details
Enrolling now

AtLAS-A Trial

University of Cincinnati
NCT IDNCT04245436ClinicalTrials.gov data as of Apr 2026
Check if I qualifyBack to resultsClinicalTrials.gov
Phase

Phase 4

Target enrollment

60

Study length

about 5.7 years

Ages

12–17

Locations

1 site in OH

About this study

This trial is testing whether duloxetine or escitalopram are effective in treating anxiety and depression in adolescents. It involves a double-blind treatment period followed by an open-label, naturalistic follow-up phase lasting 2069 days.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Duloxetine
  • 2.Take Escitalopram
PhasePhase 4
DrugDuloxetine
Routeoral
Primary goalChange from Baseline in Pediatric Anxiety Rating Scale (PARS) severity score

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low11%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

duloxetine (SNRI; increases serotonin and norepinephrine levels), escitalopram (SSRI; increases serotonin availability)

Drug routes

oral (Delayed Release Oral Capsule), oral (Oral Tablet)

Endpoints

Primary: Change from Baseline in Pediatric Anxiety Rating Scale (PARS) severity score, Change from Baseline in the Clinical Global Impression of Severity (CGI-S)

Body systems

Psychiatry / Mental Health

Check if I qualifyView on ClinicalTrials.gov